FDA Sets Review Period to Extend Diamondback Atherectomy Device Patent
Published Date: 9/29/2025
Notice
Summary
The FDA has officially set the review period for the DIAMONDBACK 360 heart device, helping its makers extend their patent protection. This means the company can get extra time to keep their invention exclusive, which could impact when generic versions appear. If you’re in the medical device world, this timing update is a big deal for innovation and competition.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Review Period for DIAMONDBACK 360
The FDA has officially determined the regulatory review period for the DIAMONDBACK 360 CORONARY ORBITAL ATHERECTOMY DEVICE and published a notice of that determination. That determination was made because the company submitted an application to the Director of the U.S. Patent and Trademark Office seeking extension of a patent that claims this medical device, which can give the maker extra time of exclusivity and may affect when competing versions appear.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in